Longeveron Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
38
- Stock Symbol
-
LGVN
- Share Price
-
$1.66
- (As of Friday Closing)
Longeveron General Information
Description
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Contact Information
Website
www.longeveron.comCorporate Office
- Life Science & Technology Park, 1951 North West 7th Avenue
- Suite 520
- Miami, FL 33136
- United States
Corporate Office
- Life Science & Technology Park, 1951 North West 7th Avenue
- Suite 520
- Miami, FL 33136
- United States
Longeveron Timeline
Longeveron Stock Performance
As of 20-Nov-2026, Longeveron’s stock price is $1.66. Its current market cap is $5.6M with 3.37M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.66 | $1.82 | $1.31 - $12.30 | $5.6M | 3.37M | 115K | -$7.95 |
Longeveron Financials Summary
As of 30-Sep-2026, Longeveron has a trailing 12-month revenue of $1.17M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (920) | 2,533 | 4,489 | 32,398 |
| Revenue | 1,165 | 1,199 | 2,392 | 709 |
| EBITDA | (21,411) | (21,478) | (15,015) | (20,467) |
| Net Income | (22,388) | (22,704) | (15,973) | (21,413) |
| Total Assets | 12,015 | 10,261 | 25,558 | 12,078 |
| Total Debt | 412 | 824 | 1,447 | 2,041 |
Longeveron Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Longeveron Comparisons
Industry
Financing
Details
Longeveron Competitors (9)
One of Longeveron’s 9 competitors is Lisata Therapeutics, a Corporation company based in Basking Ridge, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Coya Therapeutics | Formerly VC-backed | Houston, TX | ||||
| Cynata Therapeutics | Corporation | Cremorne, Australia | ||||
| BioCardia | Formerly VC-backed | Sunnyvale, CA | ||||
| Brainstorm Cell Therapeutics | Corporation | New York, NY |
Longeveron Signals
Longeveron Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Longeveron ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Longeveron FAQs
-
When was Longeveron founded?
Longeveron was founded in 2014.
-
Where is Longeveron headquartered?
Longeveron is headquartered in Miami, FL.
-
What is the size of Longeveron?
Longeveron has 38 total employees.
-
What industry is Longeveron in?
Longeveron’s primary industry is Drug Discovery.
-
Is Longeveron a private or public company?
Longeveron is a Public company.
-
What is Longeveron’s stock symbol?
The ticker symbol for Longeveron is LGVN.
-
What is the current stock price of Longeveron?
As of 20-Nov-2026 the stock price of Longeveron is $1.66.
-
What is the current market cap of Longeveron?
The current market capitalization of Longeveron is $5.6M.
-
What is Longeveron’s current revenue?
The trailing twelve month revenue for Longeveron is $1.17M.
-
Who are Longeveron’s competitors?
Lisata Therapeutics, Coya Therapeutics, Cynata Therapeutics, BioCardia, and Brainstorm Cell Therapeutics are some of the 9 competitors of Longeveron.
-
What is Longeveron’s annual earnings per share (EPS)?
Longeveron’s EPS for 12 months was -$7.95.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process